4//SEC Filing
HUFF CURTIS W 4
Accession 0000899243-23-017414
CIK 0000748592other
Filed
Jul 17, 8:00 PM ET
Accepted
Jul 18, 6:10 AM ET
Size
13.0 KB
Accession
0000899243-23-017414
Insider Transaction Report
Form 4
Freebird Partners LP
10% Owner
Transactions
- Purchase
Convertible Note Shares
2023-07-14$2.86/sh+262,237$749,998→ 262,237 totalExercise: $2.86From: 2023-07-14Exp: 2028-07-14→ Common Stock, par value $0.005 per share (262,237 underlying) - Purchase
Common Stock Purchase Warrant
2023-07-14+524,474→ 949,402 totalExercise: $2.61From: 2023-07-14Exp: 2028-07-14→ Common Stock, par value $0.005 per share (524,474 underlying)
Freebird Investments LLC
10% Owner
Transactions
- Purchase
Convertible Note Shares
2023-07-14$2.86/sh+262,237$749,998→ 262,237 totalExercise: $2.86From: 2023-07-14Exp: 2028-07-14→ Common Stock, par value $0.005 per share (262,237 underlying) - Purchase
Common Stock Purchase Warrant
2023-07-14+524,474→ 949,402 totalExercise: $2.61From: 2023-07-14Exp: 2028-07-14→ Common Stock, par value $0.005 per share (524,474 underlying)
HUFF CURTIS W
10% Owner
Transactions
- Purchase
Convertible Note Shares
2023-07-14$2.86/sh+262,237$749,998→ 262,237 totalExercise: $2.86From: 2023-07-14Exp: 2028-07-14→ Common Stock, par value $0.005 per share (262,237 underlying) - Purchase
Common Stock Purchase Warrant
2023-07-14+524,474→ 949,402 totalExercise: $2.61From: 2023-07-14Exp: 2028-07-14→ Common Stock, par value $0.005 per share (524,474 underlying)
Footnotes (2)
- [F1]This report is filed jointly by Freebird Partners LP, a Texas limited partnership ("Freebird Partners"), Freebird Investments LLC, a Texas limited liability company ("Freebird Investments"), and Curtis W. Huff (each a "Reporting Person" and collectively, the "Reporting Persons") in connection with their respective direct and indirect ownership of common stock, par value $0.005 ("Common Stock") of Eterna Therapeutics Inc. (the "Company"). These securities of the Company are held of record by Freebird Partners. Freebird Investments serves as the general partner of Freebird Partners. Curtis W. Huff is the sole member of Freebird Investments. By virtue of these relationships, each of Freebird Investments and Mr. Huff may be deemed to share beneficial ownership of the securities held of record by Freebird Partners.
- [F2]On July 13, 2023, Freebird Partners entered into that certain Securities Purchase Agreement (the "Agreement"), pursuant to which Freebird Partners agreed to purchase, and the Company agreed to sell, for an aggregate purchase price of $750,000, (i) a Senior Convertible Note in the principal amount of $750,000 (the "Note") with a five (5) year term, and (ii) a warrant to purchase up to 524,474 shares of Common Stock (the "Warrant" and such transactions the "Transactions". The Transactions closed on July 14, 2023. The Note may be converted at any time and from time to time after July 14, 2023, at the option of the holder, at a conversion price of $2.86 per share of Common Stock. The Warrant becomes exercisable on July 14, 2023, and may be exercised through July 14, 2028, at an exercise price of $2.61 per share of Common Stock.
Documents
Issuer
Eterna Therapeutics Inc.
CIK 0000748592
Entity typeother
Related Parties
1- filerCIK 0001250127
Filing Metadata
- Form type
- 4
- Filed
- Jul 17, 8:00 PM ET
- Accepted
- Jul 18, 6:10 AM ET
- Size
- 13.0 KB